Onconetix, INC

Onconetix, Inc. announced a $750 million at-the-market equity offering facility and a $30.25 million private placement of Series F convertible preferred stock.

Onconetix, Inc. is implementing a 1-for-10 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Onconetix, Inc. reports the resignation of two directors and the appointment of Josh Epstein to the Board of Directors.

Onconetix, Inc. announces the appointment of David White as CEO and Sammy Dorf to its Board, alongside a board resignation and compensation adjustments.

Onconetix, Inc. announced the appointment of David White as Chief Executive Officer, the resignation of Timothy Ramdeen from the Board, and the appointment of Sammy Dorf as a new director.

Onconetix, Inc. announced a definitive agreement to acquire Realbotix LLC in an all-stock transaction, marking a strategic shift from biotechnology to AI-powered humanoid robotics.

Onconetix reports a significant revenue decline and substantial goodwill impairment in Q1 2026, while progressing with the Realbotix merger and facing ongoing going concern doubts.

Onconetix, Inc. reported a significant revenue decline and continued operating losses in its Q3 2025 filing, despite recent capital raises and debt restructuring, raising substantial doubt about its ability to continue as a going concern.

Onconetix, Inc. reports substantial losses and a going concern warning, pivoting to a merger with Ocuvex Therapeutics while grappling with significant debt and product abandonment.

Onconetix, Inc. reported a significant revenue decline and substantial operating losses for Q1 2025, raising substantial doubt about its ability to continue as a going concern, while pivoting its focus to Proclarix prostate cancer diagnostics and pursuing a potential merger with Ocuvex Therapeutics.

Onconetix's Q3 2024 report reveals a net loss of $3.8 million and significant financial challenges, including substantial doubt about its ability to continue as a going concern.

Onconetix reports a net loss of $14.3 million for Q2 2024 and faces substantial doubt about its ability to continue as a going concern due to limited cash reserves and significant debt obligations.

Onconetix, a commercial-stage biotech, is moving forward with a reverse merger to acquire Realbotix, aiming to bolster its financial position and product pipeline while grappling with significant losses and internal control weaknesses.

Onconetix, Inc. reported a substantial net loss of $58.7 million for 2024, a significant working capital deficit, and explicit doubts about its ability to continue as a going concern, while abandoning its ENTADFI commercialization to focus on the Proclarix prostate cancer diagnostic.

Onconetix, Inc. details its capital structure, recent acquisitions, and a strategic shift towards mens health and oncology in its annual 10-K filing.

Onconetix's subsidiary Realbotix is launching a UK pilot program using humanoid robots to combat social isolation among the elderly, partnering with Bloom Procurement Services.

Realbotix, the pending acquisition target of Onconetix, has launched an AI-powered teachers assistant and humanoid robot pilot program in a New York school district.

HRT Financial LP reports significant transactions in Onconetix, Inc. Class A Shares, acquiring 49,710 shares.

HRT FINANCIAL LP reports significant transactions in Onconetix, Inc. Class A Shares.

HRT Financial LP acquired 166,904 shares of Onconetix, Inc. across two transactions on April 14 and April 15, 2026.

Onconetix, Inc. highlights the launch of Realbotix's Vinci AI Vision System, enabling humanoid robots to recognize individuals and recall conversations, following Onconetix's pending acquisition of Realbotix LLC.

Onconetix calls an April 30, 2026 special meeting to authorize one or more reverse stock splits to support Nasdaq compliance, with an aggregate limit of 1-for-100 and a one-year execution window.

Onconetix, Inc. is calling a special meeting of stockholders to vote on a reverse stock split proposal aimed at maintaining its Nasdaq listing and improving stock marketability.

Onconetix, Inc. calls for its Annual Meeting to approve significant private placement financings, elect new directors, and ratify its independent auditor.

Onconetix is seeking stockholder approval for a reverse stock split to increase its stock price and regain compliance with Nasdaq listing requirements.

Onconetix, Inc. has entered into agreements for a $2 million private placement (PIPE) and a committed equity facility (ELOC) to bolster its working capital.

Onconetix is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq listing requirements after receiving notices regarding minimum bid price and stockholders' equity.

Onconetix, Inc. has filed an amendment to its Form S-1 registration statement, primarily to include an exhibit containing a legal opinion regarding the securities being registered.

Onconetix, Inc. is registering nearly 30 million shares for resale by institutional investors, while simultaneously facing substantial doubt about its ability to continue as a going concern and abandoning its ENTADFI product.

Onconetix, a commercial-stage biotechnology company, filed an S-1 registration statement for the resale of 22,071,891 shares of common stock by selling stockholders, following recent Series D and E PIPE financings and ongoing financial challenges.

Onconetix, a commercial-stage biotech, filed an S-1 to register 5.1 million common shares for resale by Keystone Capital Partners under an existing equity line of credit, while facing significant financial challenges and abandoning a key product.

Onconetix, Inc. has filed an amendment to its Form S-1 registration statement to register the potential sale of up to 50,000,000 shares of common stock through an equity line of credit with Keystone Capital Partners, LLC, aiming to raise up to $25 million.

Onconetix, Inc. has filed an S-1 registration statement to allow for the potential sale of up to 50 million shares of common stock by Keystone Capital Partners, LLC through an equity line of credit.

Altos Venture AG significantly increased its beneficial ownership in Onconetix, Inc. to 35.8% of outstanding common stock after receiving 241,514 additional shares under a 'make-whole' provision.

Christian Bruhlmann, Chief Strategy Officer of Onconetix, Inc., filed an amended Schedule 13D to update his beneficial ownership to 4.20% of common stock, reflecting a recent RSU grant and the expiration of a lock-up agreement.

Onconetix, Inc. has filed an amended Schedule 13D revealing that Interim CEO and Chief Science Officer Ralph Schiess's beneficial ownership now stands at 4.63% after receiving a grant of restricted stock units and the conversion of preferred stock related to the Proteomedix acquisition.

Keystone Capital Partners, RANZ Group, and Fredric Zaino have jointly filed a Schedule 13G, reporting beneficial ownership of 223,717 shares of Onconetix, Inc. common stock, representing 6.1% of the outstanding shares.

American Financial Group, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 36,023 common shares, representing 0.0% of ONCONETIX, INC.

Zurcher Kantonalbank (Zurich Cantonalbank) has filed an amended Schedule 13G, reporting a passive beneficial ownership of 2.5% in Onconetix, Inc.'s common stock as of December 24, 2024.